• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌的组织病理学评估和分级:当前的问题和关键方面。

Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects.

机构信息

Section of Pathology, Department of Molecular and Translational Medicine, University of Brescia, Brescia 25121, Italy.

Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona 37126, Italy.

出版信息

Asian J Androl. 2024 Nov 1;26(6):575-581. doi: 10.4103/aja202440. Epub 2024 Sep 10.

DOI:10.4103/aja202440
PMID:39254403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11614181/
Abstract

A crucial aspect of prostate cancer grading, especially in low- and intermediate-risk cancer, is the accurate identification of Gleason pattern 4 glands, which includes ill-formed or fused glands. However, there is notable inconsistency among pathologists in recognizing these glands, especially when mixed with pattern 3 glands. This inconsistency has significant implications for patient management and treatment decisions. Conversely, the recognition of glomeruloid and cribriform architecture has shown higher reproducibility. Cribriform architecture, in particular, has been linked to the worst prognosis among pattern 4 subtypes. Intraductal carcinoma of the prostate (IDC-P) is also associated with high-grade cancer and poor prognosis. Accurate identification, classification, and tumor size evaluation by pathologists are vital for determining patient treatment. This review emphasizes the importance of prostate cancer grading, highlighting challenges like distinguishing between pattern 3 and pattern 4 and the prognostic implications of cribriform architecture and intraductal proliferations. It also addresses the inherent grading limitations due to interobserver variability and explores the potential of computational pathology to enhance pathologist accuracy and consistency.

摘要

前列腺癌分级的一个关键方面,特别是在低危和中危癌症中,是准确识别格里森 4 型腺体,其中包括形态不规则或融合的腺体。然而,病理学家在识别这些腺体方面存在显著的不一致性,尤其是当它们与 3 型腺体混合时。这种不一致性对患者的管理和治疗决策有重大影响。相反,肾小球样和筛状结构的识别显示出更高的可重复性。特别是,筛状结构与 4 型亚型中最差的预后相关。前列腺导管内癌 (IDC-P) 也与高级别癌症和预后不良相关。病理学家的准确识别、分类和肿瘤大小评估对于确定患者的治疗至关重要。本综述强调了前列腺癌分级的重要性,突出了区分 3 型和 4 型、筛状结构和管内增生的预后意义等挑战。它还探讨了由于观察者间变异性导致的内在分级限制,并研究了计算病理学提高病理学家准确性和一致性的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9985/11614181/95eb823bafa9/AJA-26-575-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9985/11614181/c4121d596794/AJA-26-575-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9985/11614181/47928e0ad970/AJA-26-575-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9985/11614181/95eb823bafa9/AJA-26-575-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9985/11614181/c4121d596794/AJA-26-575-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9985/11614181/47928e0ad970/AJA-26-575-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9985/11614181/95eb823bafa9/AJA-26-575-g003.jpg

相似文献

1
Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects.前列腺癌的组织病理学评估和分级:当前的问题和关键方面。
Asian J Androl. 2024 Nov 1;26(6):575-581. doi: 10.4103/aja202440. Epub 2024 Sep 10.
2
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.2014年国际泌尿病理学会(ISUP)前列腺癌Gleason分级共识会议:分级模式的定义及新分级系统的建议
Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530.
3
Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists.Gleason 4级前列腺腺癌模式:泌尿生殖病理学家之间的观察者间一致性研究
Histopathology. 2016 Sep;69(3):441-9. doi: 10.1111/his.12976. Epub 2016 May 24.
4
Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers.2018年前列腺癌分级:局限性、实施情况、筛状形态及生物标志物
Int J Biol Markers. 2018 Nov;33(4):331-334. doi: 10.1177/1724600818781296. Epub 2018 Jun 27.
5
Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome.前列腺癌中筛状结构和 4 级 Gleason 模式比例的观察者间变异性:与临床结果的关系。
Virchows Arch. 2021 Feb;478(2):249-256. doi: 10.1007/s00428-020-02902-9. Epub 2020 Aug 20.
6
SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.SOCS3免疫组化表达似乎支持2005年和2014年国际泌尿病理学会(ISUP)改良的Gleason分级系统。
Prostate. 2017 May;77(6):597-603. doi: 10.1002/pros.23299. Epub 2017 Feb 1.
7
Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series.并非所有 Gleason 4 级前列腺癌都是一样的:一项对膀胱前列腺切除术和尸检系列中潜伏性前列腺癌的研究。
Prostate. 2015 Sep;75(12):1277-84. doi: 10.1002/pros.23009. Epub 2015 May 11.
8
Correlation of large cribriform carcinoma and "unfavorable histology" with other Gleason pattern 4 subtypes: A proof-of-principle study evaluating 485 radical prostatectomy specimens with proposal for the concept of "borderline histology".大筛状癌和“不良组织学”与其他Gleason 4级亚型的相关性:一项原理验证研究,评估485例根治性前列腺切除术标本并提出“临界组织学”概念。
Ann Diagn Pathol. 2025 Apr;75:152427. doi: 10.1016/j.anndiagpath.2024.152427. Epub 2024 Dec 5.
9
Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.前列腺导管内癌:39名泌尿外科病理学家的观察者间再现性调查
Ann Diagn Pathol. 2014 Dec;18(6):333-42. doi: 10.1016/j.anndiagpath.2014.08.010. Epub 2014 Sep 3.
10
Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.当代前列腺癌 Gleason 模式 4 的百分比和结构类型对根治性前列腺切除术预后的意义。
Am J Surg Pathol. 2016 Oct;40(10):1400-6. doi: 10.1097/PAS.0000000000000691.

引用本文的文献

1
Assessment of interobserver variability in Gleason grading for prostate carcinoma.前列腺癌Gleason分级中观察者间变异性的评估。
North Clin Istanb. 2025 Jun 23;12(3):337-343. doi: 10.14744/nci.2025.11456. eCollection 2025.
2
Inflammatory-based prognostic indicators in prostate cancer: evaluating NLR, PLR, and SII in relation to Cambridge and ISUP classifications.前列腺癌中基于炎症的预后指标:评估中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)以及全身免疫炎症指标(SII)与剑桥和国际泌尿病理学会(ISUP)分类的关系
Front Oncol. 2025 Jul 4;15:1595000. doi: 10.3389/fonc.2025.1595000. eCollection 2025.
3
The continued pursuit of new strategies and new technologies.

本文引用的文献

1
Yield of second-round MRI targeted ultrasound-guided fusion prostate biopsy after initial first-round targeted biopsy.首轮靶向活检后第二轮MRI靶向超声引导下融合前列腺活检的阳性率
Can Urol Assoc J. 2023 Aug 29;17(12):393-401. doi: 10.5489/cuaj.8366.
2
A systematic review and meta-analysis of artificial intelligence diagnostic accuracy in prostate cancer histology identification and grading.人工智能在前列腺癌组织学识别和分级中的诊断准确性的系统评价和荟萃分析。
Prostate Cancer Prostatic Dis. 2023 Dec;26(4):681-692. doi: 10.1038/s41391-023-00673-3. Epub 2023 Apr 25.
3
Prostate Pathology: What is New in the 2022 WHO Classification of Urinary and Male Genital Tumors?
对新策略和新技术的持续追求。
Asian J Androl. 2024 Nov 1;26(6):547-548. doi: 10.4103/aja202491. Epub 2024 Oct 11.
前列腺病理学:2022 年世卫组织泌尿系统和男性生殖器官肿瘤分类有哪些新内容?
Pathologica. 2022 Feb;115(1):41-56. doi: 10.32074/1591-951X-822. Epub 2023 Jan 16.
4
Prostate Cancer: Update on Grading and Reporting.前列腺癌:分级和报告的最新进展。
Surg Pathol Clin. 2022 Dec;15(4):579-589. doi: 10.1016/j.path.2022.07.008. Epub 2022 Oct 13.
5
Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis.前列腺癌患者筛状组织学模式的肿瘤学结局:系统评价和荟萃分析。
Prostate Cancer Prostatic Dis. 2023 Dec;26(4):646-654. doi: 10.1038/s41391-022-00600-y. Epub 2022 Oct 10.
6
Sensitivity of multiparametric MRI and targeted biopsy for detection of adverse pathologies (Cribriform gleason pattern 4 and intraductal carcinoma): Correlation of detected and missed prostate cancer foci with whole mount histopathology.多参数 MRI 和靶向活检检测不良病理(筛状格里森 4 级和导管内癌)的敏感性:全切除组织病理学检测到和漏诊的前列腺癌病灶的相关性。
Urol Oncol. 2022 Oct;40(10):452.e1-452.e8. doi: 10.1016/j.urolonc.2022.07.012. Epub 2022 Aug 23.
7
The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors.《2022 年世界卫生组织泌尿系统及男性生殖器官肿瘤分类-第 B 部分:前列腺和泌尿系统肿瘤》。
Eur Urol. 2022 Nov;82(5):469-482. doi: 10.1016/j.eururo.2022.07.002. Epub 2022 Aug 11.
8
WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer.《世界卫生组织肿瘤分类第五版:前列腺癌分类、诊断和预后的演进问题》
Histopathology. 2022 Oct;81(4):447-458. doi: 10.1111/his.14711. Epub 2022 Aug 2.
9
Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.人工智能在前列腺癌诊断和 Gleason 分级中的应用:PANDA 挑战赛。
Nat Med. 2022 Jan;28(1):154-163. doi: 10.1038/s41591-021-01620-2. Epub 2022 Jan 13.
10
Prognostic value of cribriform size, percentage, and intraductal carcinoma in Gleason score 7 prostate cancer with cribriform Gleason pattern 4.前列腺癌具有筛状结构且 Gleason 评分为 4 分的情况下,筛状结构大小、比例和导管内癌对 Gleason 评分 7 的预后价值。
Hum Pathol. 2021 Dec;118:18-29. doi: 10.1016/j.humpath.2021.09.005. Epub 2021 Sep 17.